An immunohistochemistry analysis of the MMR proteins is thus the first step in discriminating LS and sporadic MSI/dMMR tumors, since the combined loss of MSH2 and MSH6 or the isolated loss of MSH6 or PMS2 will argue for a LS-related tumor. The gene discussed is PMS2; the disease is neoplasm.